These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15629627)

  • 1. Establishing a prognostic score for primary CNS lymphomas.
    Ferreri AJ; Reni M
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):303-4; author reply 304-5. PubMed ID: 15629627
    [No Abstract]   [Full Text] [Related]  

  • 2. Cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment?
    Salmaggi A; Eoli M; Corsini E; Gelati M; Frigerio S; Silvani A; Boiardi A
    Ann Neurol; 2000 Jan; 47(1):137-8. PubMed ID: 10632117
    [No Abstract]   [Full Text] [Related]  

  • 3. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
    Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
    Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system.
    Jahnke K; Thiel E; Martus P; Schwartz S; Korfel A
    Ann Hematol; 2006 Jan; 85(1):45-50. PubMed ID: 16132909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system-directed preventative therapy in adults with lymphoma.
    McMillan A
    Br J Haematol; 2005 Oct; 131(1):13-21. PubMed ID: 16173958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL13 and CXCL12 in central nervous system lymphoma patients.
    Fischer L; Korfel A; Pfeiffer S; Kiewe P; Volk HD; Cakiroglu H; Widmann T; Thiel E
    Clin Cancer Res; 2009 Oct; 15(19):5968-73. PubMed ID: 19773382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of selected clinical prognostic factors in patients with non-granulomatous lymphomas].
    Rolski J
    Pol Merkur Lekarski; 1997 May; 2(11):324-6. PubMed ID: 9377682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic factors in non-Hodgkin's lymphomas].
    Mayáns J; Sanz G; Monzó E; Sancho-Tello R; Carrera MD; Figueres J; Sanz MA
    Rev Clin Esp; 1987 May; 180(8):420-5. PubMed ID: 3616025
    [No Abstract]   [Full Text] [Related]  

  • 9. [Large-cell lymphomas: the International Prognostic Index].
    López Guillermo A; Montserrat E
    Sangre (Barc); 1992 Oct; 37(5):329-30. PubMed ID: 1293770
    [No Abstract]   [Full Text] [Related]  

  • 10. [How and why have the old drugs changed the prognosis of patients with the primary CNS lymphoma?].
    Klabusay M
    Vnitr Lek; 2010 Aug; 56(8):785-6. PubMed ID: 20845608
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.
    Imai H; Shimada K; Shimada S; Abe M; Okamoto M; Kitamura K; Kinoshita T; Shiraishi T; Nakamura S
    Pathol Int; 2009 Jul; 59(7):431-7. PubMed ID: 19563405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor markers in malignant lymphoma].
    Kato H; Ogura M
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
    Ferreri AJ; Dell'Oro S; Foppoli M; Bernardi M; Brandes AA; Tosoni A; Montanari M; Balzarotti M; Spina M; Ilariucci F; Zaja F; Stelitano C; Bobbio F; Corazzelli G; Baldini L; Ponzoni M; Picozzi P; Caligaris Cappio F; Reni M
    Neurology; 2006 May; 66(9):1435-8. PubMed ID: 16682682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.
    D'Haene N; Catteau X; Maris C; Martin B; Salmon I; Decaestecker C
    Br J Haematol; 2008 Feb; 140(4):402-10. PubMed ID: 18081894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost determinants in aggressive non-Hodgkin's lymphoma.
    van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
    Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
    Seve P; Ray-Coquard I; Trillet-Lenoir V; Sawyer M; Hanson J; Broussolle C; Negrier S; Dumontet C; Mackey JR
    Cancer; 2006 Dec; 107(11):2698-705. PubMed ID: 17063500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma.
    Watanabe J; Natsumeda M; Kanemaru Y; Okada M; Oishi M; Kakita A; Fujii Y
    Leuk Lymphoma; 2019 Dec; 60(14):3587-3589. PubMed ID: 31305194
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
    Broyde A; Boycov O; Strenov Y; Okon E; Shpilberg O; Bairey O
    Am J Hematol; 2009 Jun; 84(6):338-43. PubMed ID: 19384938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
    Yamashita H; Izutsu K; Nakamura N; Shiraishi K; Chiba S; Kurokawa M; Tago M; Igaki H; Ohtomo K; Nakagawa K
    Ann Hematol; 2006 Aug; 85(8):523-9. PubMed ID: 16691398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.